
ALXO Stock Forecast & Price Target
ALXO Analyst Ratings
Bulls say
ALX Oncology Holdings Inc is advancing its clinical-stage immuno-oncology pipeline with promising candidates such as the CD47 blocker, evorpacept, currently undergoing phase 1 and 2 clinical trials, alongside the recently added EGFR-targeting ADC, ALX2004, which is designed to enhance safety and efficacy. The company has reported promising metrics, including a median progression-free survival (mPFS) of approximately 7 months in its TRP control group, outperforming industry benchmarks and indicating the potential for durable patient responses. Additionally, combination studies involving evorpacept with anti-HER2 antibodies have shown strong efficacy, particularly in HER2-positive breast cancer, reinforcing the company’s optimistic developmental outlook.
Bears say
ALX Oncology Holdings Inc. has experienced a downward revision in its peak penetration rate estimate for Head and Neck cancer, decreased from 25% to 10%, reflecting concerns over the competitive landscape in oncology treatments. The company reported no revenues for 4Q24 and a net loss per share of $0.55, which, while slightly better than consensus estimates, indicates ongoing financial struggles amidst heightened uncertainty regarding its clinical trial outcomes and the potential for FDA rejection. Furthermore, the anticipated data from interim phase 2 results for breast and colorectal cancer (CRC) will not be available until 2026, contributing to a lack of confidence in the company's near-term growth prospects and financial stability.
This aggregate rating is based on analysts' research of ALX Onconology Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ALXO Analyst Forecast & Price Prediction
Start investing in ALXO
Order type
Buy in
Order amount
Est. shares
0 shares